degarelix acetate · Ferring · NDA 022201
Firmagon
Earliest generic entry, as listed · earliest of 2 marketed strengths
27 Apr 2032
Blocked by patent: US 10695398, US 11766468, US 11826397, US 9415085. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10695398 | use U-1895 | 27 Apr 2032 |
| US 11766468 | use U-1978 | 27 Apr 2032 |
| US 11826397 | use U-1978 | 27 Apr 2032 |
| US 9415085 | use U-1895 | 27 Apr 2032 |
| US 12514898 | use U-1978 | 20 Feb 2029 |
| US 12533387 | use U-4417 | 20 Feb 2029 |
| US 10729739 | use U-1978 | 10 Feb 2029 |
| US 10973870 | use U-1978 | 10 Feb 2029 |
| US 9579359 | use U-1978 | 10 Feb 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022201 · 001 · RLD | powder, subcutaneous | EQ 80MG BASE/VIAL | 27 Apr 2032 |
| 022201 · 002 · RLD | powder, subcutaneous | EQ 120MG BASE/VIAL | 27 Apr 2032 |